Literature DB >> 32827132

CpG Oligonucleotides as Vaccine Adjuvants.

Neslihan Kayraklioglu1, Begum Horuluoglu1, Dennis M Klinman2,3.   

Abstract

CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid dendritic cells and B cells and triggers an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. This chapter reviews recent progress in understanding the mechanism of action of CpG ODN and provides an overview of human clinical trial results using CpG ODN to improve vaccines for the prevention/treatment of cancer, allergy, and infectious disease.

Entities:  

Keywords:  Adjuvant; Allergy; Cancer; CpG motif; DNA vaccine; Infection; TLR9; Toll-like receptors

Mesh：

Substances：

Year:  2021        PMID： 32827132     DOI： 10.1007/978-1-0716-0872-2_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  14 in total

1.  Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.

Authors:  Jeroen Pollet; Ulrich Strych; Wen-Hsiang Chen; Leroy Versteeg; Brian Keegan; Bin Zhan; Junfei Wei; Zhuyun Liu; Jungsoon Lee; Rahki Kundu; Rakesh Adhikari; Cristina Poveda; Maria Jose Villar; Syamala Rani Thimmiraju; Brianna Lopez; Portia M Gillespie; Shannon Ronca; Jason T Kimata; Martin Reers; Vikram Paradkar; Peter J Hotez; Maria Elena Bottazzi
Journal:  Vaccine       Date:  2022-05-08       Impact factor: 4.169

2.  Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.

Authors:  Khue G Nguyen; Siena M Mantooth; Maura R Vrabel; David A Zaharoff
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 3.  Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.

Authors:  Noémi Anna Nagy; Aram M de Haas; Teunis B H Geijtenbeek; Ronald van Ree; Sander W Tas; Yvette van Kooyk; Esther C de Jong
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 4.  Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19.

Authors:  Nicholas Stoy
Journal:  Front Immunol       Date:  2021-04-07       Impact factor: 7.561

Review 5.  Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics.

Authors:  Juergen Scharner; Isabel Aznarez
Journal:  Mol Ther       Date:  2020-12-25       Impact factor: 11.454

6.  A Combined Adjuvant TF-Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice.

Authors:  Qiao Li; Zhihua Liu; Yi Liu; Chen Liang; Jiayi Shu; Xia Jin; Chuanyou Li; Zhihua Kou
Journal:  Vaccines (Basel)       Date:  2021-11-29

7.  Free Feeding of CpG-Oligodeoxynucleotide Particles Prophylactically Attenuates Allergic Airway Inflammation and Hyperresponsiveness in Mice.

Authors:  Takuma Okajima; Suguru Shigemori; Fu Namai; Tasuku Ogita; Takashi Sato; Takeshi Shimosato
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

8.  CpG Oligodeoxynucleotides Attenuate OVA-Induced Allergic Airway Inflammation via Suppressing JNK-Mediated Endoplasmic Reticulum Stress.

Authors:  Hai-Yun Zhang; Qiu-Meng Xie; Cui-Cui Zhao; Jia-Feng Sha; Ya Ruan; Hui-Mei Wu
Journal:  J Asthma Allergy       Date:  2021-11-17

Review 9.  Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases.

Authors:  Jing-Xing Yang; Jen-Chih Tseng; Guann-Yi Yu; Yunping Luo; Chi-Ying F Huang; Yi-Ren Hong; Tsung-Hsien Chuang
Journal:  Pharmaceutics       Date:  2022-02-16       Impact factor: 6.525

10.  Astragalus Polysaccharides Enhance the Immune Response to OVA Antigen in BALB/c Mice.

Authors:  Yumei Zhou; Yuhan Zong; Zihao Liu; Haihong Zhao; Xiaoshan Zhao; Ji Wang
Journal:  Biomed Res Int       Date:  2021-06-28       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.